3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
24
Hereditary Sensory and Autonomic Neuropathies
6
Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Ovarian Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Head and Neck Neoplasms
2
Advanced Breast Cancer
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
1
Pre-menopausal Breast Cancer
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphatic Abnormalities
1
Lymphangioma, Cystic
1
Lymphangioma
1
Kidney Neoplasms
1
Hyperglycemia
1
HER2-positive Metastatic Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Advanced or Metastatic ER+ Breast Cancer
1
Advanced and Selected Solid Tumors
1
Advanced Solid Tumors With an Alteration of the PIK3CA Gene
1
Advanced Solid Tumor
1
Advanced HER2+Breast Cancer
1
Interventions
pembrolizumab
75
Carboplatin
46
Paclitaxel
44
130-nm albumin-bound paclitaxel
35
Gemcitabine
34
Cyclophosphamide
23
Capecitabine
22
Nivolumab
21
Albumin-Bound Paclitaxel
21
atezolizumab
20
sacituzumab govitecan
14
spartalizumab
13
Doxorubicin
11
olaparib
9
Cisplatin
9
Bevacizumab
9
eribulin
8
fludarabine
7
durvalumab
7
avelumab
7
Injections
7
Fulvestrant
7
Fluorouracil
7
Vinorelbine
6
Leucovorin
6
Docetaxel
6
iniparib
5
budigalimab
5
Ipilimumab
5
Epirubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Triple Negative Breast Neoplasms
×
Alpelisib
×
Clear all
NCT04251533
2026-05-11
EPIK-B3
Novartis
Phase 3
Terminated
137 enrolled
21 charts